Natural Alternatives International Inc

Natural Alternatives International Inc operates with a low debt-to-equity ratio of 0.11 and a strong current ratio of 3.98, indicating robust short-term liquidity. The company's price-to-book ratio of 0.2 and price-to-tangible-book ratio of 0.2 suggest that the market values the company significantly below its book value, potentially reflecting concerns about asset quality or future earnings potential.

The company's profitability metrics are weak, with a negative return on equity of -1.88% and a negative return on assets of -1.03%. These figures fall below typical industry benchmarks for pharmaceutical and personal care product companies, indicating underperformance relative to its peers.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases exposure to market-specific risks and limits growth opportunities.

The company's growth trajectory is uncertain, with no significant revenue growth reported in the latest financial period. The operating cash flow of $1.22 million is modest, and the free cash flow is negative at -$754,000, suggesting that the company is not generating sufficient cash to fund operations and capital expenditures without external financing.

The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the negative net income of -$1.58 million and the operating loss of -$1.95 million indicate financial stress that could necessitate future equity or debt financing, potentially leading to dilution.

Recent filings and transcripts do not indicate any major strategic shifts or significant events that would alter the company's current financial trajectory. The company continues to focus on its core personal care product lines and private label arrangements.

Revenue grew 14.1% year-over-year to $129.9 million, demonstrating top-line expansion despite recent profitability challenges.

The company maintains a low debt-to-equity ratio of 0.11, which is above the pharmaceutical cohort median of 0.18.

Liquidity risk is assessed as low, supported by a current ratio of 2.06 as of June 2025.

Dilution risk is rated low, suggesting limited immediate pressure on shareholder equity from share issuance.

Gross profit reached $9.3 million in the latest period, indicating some margin preservation despite net losses.

Credit risk is flagged as high, indicating significant concerns regarding the company's ability to meet debt obligations.